Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937452 | 0.89 | NPC1 (0.39) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL4936238 | 0.89 | MKNK1 (0.46) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL4939677 | 0.87 | NPC1 (0.37) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL14027879 | 0.79 | ABL1 (0.38) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL14027866 | 0.79 | AVPR2 (0.44) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL4937180 | 0.78 | NPC1 (0.40) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL14027870 | 0.78 | TLR7 (0.38) | MKNK1MKNK2AVPR2AVPR1AL3MBTL1 | |
| SCHEMBL4938205 | 0.78 | NPC1 (0.40) | MKNK1MKNK2AVPR2AVPR1AMTOR | |
| SCHEMBL4936885 | 0.77 | NPC1 (0.41) | AVPR2AVPR1ARIPK1NPC1ABL1 | |
| SCHEMBL4939332 | 0.77 | AVPR1A (0.40) | AVPR2AVPR1APOLBRIPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | MKNK1 345/4885MKNK2 348/4885AVPR2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.